Related Experiment Video
Updated: Apr 19, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
1Hepatology Department, National Liver Institute, Menoufiya University, Menoufiya, Egypt.
Summary
Hepatitis C virus genotype 4 treatment is advancing rapidly. New direct-acting antiviral regimens offer shorter durations and higher cure rates for hepatitis C patients.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) genotype 4 (HCV-4) treatment has historically relied on pegylated interferon (PEG-IFN)-ribavirin (RBV), associated with modest efficacy and significant side effects.
- The advent of direct-acting antivirals (DAAs) like sofosbuvir (SOF), simeprevir (SIM), and daclatasvir (DCV) has revolutionized HCV therapy.
Purpose of the Study:
- To review the evolving optimal therapeutic strategies for hepatitis C virus genotype 4 infection.
- To highlight the advancements in treatment regimens, focusing on efficacy, duration, and patient eligibility.
Main Methods:
- Review of current and emerging treatment guidelines for HCV genotype 4.
- Analysis of clinical trial data for direct-acting antiviral combinations.
Main Results:
- For interferon-eligible patients, PEG-IFN/RBV combined with SOF, SIM, or DCV shows improved outcomes.
- Interferon-ineligible patients benefit from 24-week SOF/RBV or 12-week SOF-SIM or SOF-DCV regimens, with or without RBV.
- Upcoming interferon-free regimens (e.g., paritaprevir-ombitasvir, SOF-ledipasvir, DCV-ASV-beclabuvir) promise near 100% cure rates in under 12 weeks.
Conclusions:
- Direct-acting antiviral therapies have significantly improved treatment outcomes for HCV genotype 4, shortening treatment duration and increasing cure rates.
- Future interferon-free regimens are expected to become the new standard of care, offering highly effective and rapid eradication of HCV-4 infection.
Related Concept Videos
01:25Hepatitis
66
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
66
01:10Retrovirus Life Cycles
50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
01:30Inhibitors of Viral Protein Synthesis
47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
01:28Viral Hepatitis I: Introduction
15
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
15
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
365
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
365
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K